BioMedNewsBreaks

ThursdayNov 10, 2022 12:06 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at ‘Exploring the Neuroprotective Qualities of Rare Cannabinoids’ Webinar Event

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced that its CEO Eric A. Adams and SVP of Preclinical Research and Development Eric Hsu will present at Tribe Public’s upcoming webinar presentation and Q&A event. Titled “Exploring the Neuroprotective Qualities of Rare Cannabinoids,” the event is scheduled to begin at 8:30 a.m. Pacific Time on Nov. 17, 2022. Interested parties should visit https://ibn.fm/5WHrj to register for and join the complimentary, Zoom webinar-based event. Once registered, participants may begin forwarding their questions for InMed’s management to Tribe Public at…

Continue Reading

MondayNov 07, 2022 1:50 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Targeted ‘Finish Line Is Within Sight’ as It Pursues Potential GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) has been developing drug candidates for treating primary and metastatic brain and central nervous system cancer. “Berubicin, the company’s lead drug candidate, is a novel anthracycline in an ongoing international trail in glioblastoma (“GBM”) treatment. The interim analysis data from this potentially pivotal trial is expected in mid-2023… Berubicin was the first [anthracycline] to provide scientific data which appears to demonstrate its ability to cross the blood-brain barrier and was designed with a molecular target of topoisomerase II enzymes responsible for cleaving and recombing double-stranded DNA during cellular replication,” a recent article explains. “Since the beginning…

Continue Reading

MondayNov 07, 2022 10:12 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, was featured in a recent report published by Zacks Small-Cap Research. In the report, Zacks valued BVXV at $12.00/ADS. The publication reads, “On August 25, 2022, BiondVax Pharmaceuticals Ltd. (BVXV) announced financial results for the second quarter of 2022 and provided a business update. The COVID-19 NanoAb program is proceeding on schedule, with an inhalation proof-of-concept study with the anti-SARS-CoV-2 NanoAb in COVID-19 infected animals expected to begin by the end of 2022. Based on…

Continue Reading

ThursdayNov 03, 2022 2:42 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, is focused on fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, and other rare neurological disorders. “Silo Pharma is currently developing ketamine treatments for fibromyalgia – a chronic disease that causes pain throughout the body. With no cure available, fibromyalgia can be a debilitating condition that extends beyond the pain to cause extreme fatigue, anxiety and memory issues. Silo’s novel ketamine formulation, designated as SP-26, is currently undergoing safety evaluation to treat fibromyalgia,” reads a recent article. “We are…

Continue Reading

ThursdayNov 03, 2022 1:18 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at RAFT 14 Conference

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that its Head of Technical R&D, Dr. Dalit Weinstein Fischer, will attend and present at Recent Advances in Fermentation Technology (“RAFT”) 14. The conference of the Society for Industrial Microbiology and Biotechnology (“SIMB”) is taking place from Nov. 6 to 9, 2022, in Orlando, Florida. RAFT provides academic and industrial scientists a forum to discuss the latest developments in fermentation technology. Dr. Fischer’s presentation, slated to begin at 3:35 p.m. ET on Nov.…

Continue Reading

ThursdayNov 03, 2022 12:58 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Expansion of Executive Team

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, is expanding its executive team. The expansion is part of ODYY’s support of and commitment to Odyssey NeuroPharma, the company’s newest entity. Additions to the executive team include Erik Emerson, named chief commercial officer, and Greg Gironda, named chief operating officer. These two together have more than five decades of experience in commercializing innovative pharmaceutical compounds with leading pharmaceutical companies; the pair will work to advance Odyssey’s concussion treatment and Niemann-Pick treatment. According to the announcement, more than 5 million…

Continue Reading

ThursdayNov 03, 2022 11:16 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation Schedule for Upcoming Investor Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s Chief Executive Officer Doug Drysdale will present and host investor meetings at the Jefferies London Healthcare Conference taking place on Nov. 15-17, 2022. Drysdale’s presentation is slated to begin at 8:00 a.m. GMT on Nov. 15. Drysdale will also participate in a panel discussion titled “Psychedelics Landscape – What can we expect?” at 5:00 p.m. GMT on Nov. 16, 2022, at the Pinsent Masons Psychedelics Panel in London, U.K. In addition, Drysdale will participate in…

Continue Reading

WednesdayNov 02, 2022 12:45 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT) Selects POD Group’s Advanced Connectivity Solutions for SmartSole(TM) Platform

MetAlert (OTC: MLRT), a pioneer in the field of wearable GPS human and asset tracking and remote patient monitoring, has selected Pod Group’s ENO ONE IoT SIM cards and advanced connectivity solutions for enterprise IoT applications for its award-winning, two-way GPS SmartSole. A wearable medical monitoring device, SmartSole is integrated into an orthotic insole allowing discreet and unobtrusive tracking and remote monitoring of Alzheimer’s, dementia and autism sufferers. “The POD Group partnership is a critical component for the launch of our SmartSole plus, a mobile hot spot connected to other wearable devices,” said MetAlert CEO Patrick Bertagna. “This level of…

Continue Reading

WednesdayNov 02, 2022 11:53 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has provided an update on enrollment of its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. The company announced that the first patient in Europe has been enrolled in the study and has started receiving dosages. Eventually the company plans to have 68 sites opened for the ongoing…

Continue Reading

TuesdayNov 01, 2022 12:58 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled “CYB004 — Modifications to DMT to Enhance its Therapeutic Potential,” includes an overview of the preclinical data for CYB004, Cybin’s deuterated dimethyltryptamine (DMT) program and the advantages of deuteration on its therapeutic effect. Reichelt’s presentation will begin at 1:15 p.m. ET today.“I am delighted to be…

Continue Reading